Rubicon Research Private Limited

Rubicon Research Private Limited, established on May 6, 1999, is a privately held Indian pharmaceutical company specializing in the development, manufacturing, and commercialization of generic and specialty formulations. The company is headquartered in Thane, Maharashtra, India, with its registered office at MedOne House, B-75, Road No. 33, Wagle Estate, Thane West, Thane, Maharashtra 400604.

As of the latest available data, Rubicon Research has an authorized capital of ₹238.99 crore and a paid-up capital of ₹21.045 crore. The company employs between 201 and 500 individuals, reflecting its substantial presence in the pharmaceutical sector.

In 2022, Rubicon Research reported a total export value of $94.9 million USD, with 2,208 shipments across 13 products in seven therapeutic categories. The company's top five products include Metoprolol ($26.6 million, 3.3% market share), Tramadol ($11.4 million, 3.0% market share), Iron ($9.1 million, 1.9% market share), Clonazepam ($8.4 million, 6.5% market share), and Potassium ($7.2 million, 1.1% market share).

Rubicon Research operates multiple manufacturing facilities in India, including plants in Ambernath, Satara, and Pithampur. The Ambernath facility, commissioned in 2009, is US FDA-approved and specializes in oral solids manufacturing. The Satara facility, acquired in July 2021, focuses on oral liquid and nasal product manufacturing.

The leadership team at Rubicon Research includes:

• Deep Mishra: Director since December 21, 2016.

• Bangesh Chakrabarti: Director since December 21, 2016.

• Pratibha Sudhir Pilgaonkar: Director since June 1, 2000.

• Sudhir Dhirendra Pilgaonkar: Director since May 6, 1999.

• Himanshu Nivsarkar: Director since December 17, 2012.

• Pancham Navin Mukim: Director since January 27, 2017.

• Parag Suganchand Sancheti: Director since January 27, 2017.

These individuals have been instrumental in steering the company's strategic direction and growth.

Rubicon Research has established a significant presence in regulated markets, particularly in the United States. The company has over 28 approved products in the US, with more than 70 products in development and over 10 products under review with the US FDA.

In the European Union, the company has obtained EU GMP certificates, ensuring compliance with stringent manufacturing standards. Additionally, Rubicon Research has received WHO prequalification for certain products, facilitating access to global markets.

Rubicon Research has expanded its footprint in emerging markets, including Africa, Latin America, and Southeast Asia. The WHO prequalification of some of its products has enabled the company to access these regions, enhancing its global reach and market penetration.

The company's geographic strategy demonstrates a balanced approach, with a strong focus on regulated markets such as the US and Europe, while also tapping into emerging markets through WHO prequalification. This diversification mitigates concentration risk and positions Rubicon Research for sustained growth across various regions.

Rubicon Research's manufacturing facilities in Ambernath and Satara are US FDA-approved, reflecting the company's commitment to adhering to international quality standards. The company has a robust pipeline, with over 28 approved products in the US and more than 10 products under review with the US FDA.

Rubicon Research has obtained WHO prequalification for certain products, facilitating access to global markets. The company has also secured EU GMP certificates, ensuring compliance with European manufacturing standards.

Rubicon Research holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), India's national regulatory authority. The company has also obtained state drug controller approvals and export No Objection Certificates (NOCs), enabling it to export pharmaceutical products internationally.

As of March 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Rubicon Research by the US FDA. This indicates a favorable regulatory standing for the company.

Rubicon Research operates in a competitive landscape with several key players in the generic pharmaceutical sector. The company's focus on value-added products, strong R&D capabilities, and established presence in regulated markets provide it with a competitive edge. However, it faces competition from both established multinational corporations and emerging regional players.

Rubicon Research's key differentiators include its extensive portfolio of over 28 approved products in the US, a pipeline of more than 70 products in development, and a commitment to quality evidenced by its US FDA-approved manufacturing facilities and EU GMP certifications.

Rubicon Research's strategic direction focuses on expanding its portfolio of generic and specialty products, leveraging its R&D capabilities to develop value-added formulations. The company's future outlook includes further penetration into regulated markets and emerging regions, supported by its robust manufacturing and regulatory compliance.

Rubicon Research has demonstrated a consistent track record in manufacturing and exporting pharmaceutical products, with a total export value of $94.9 million USD and 2,208 shipments across 13 products in seven therapeutic categories. The company's adherence to international quality standards and regulatory approvals underscores its reliability as a supplier.

Importers should verify the following certifications when considering Rubicon Research as a supplier:

• FDA Approval: Confirm the company's US FDA-approved manufacturing facilities and product approvals.

• WHO Prequalification: Verify the WHO prequalification status of relevant products.

• EU GMP Certification: Ensure the company holds valid EU GMP certificates for applicable products.

• ISO Certifications: Check for ISO certifications related to quality management systems.

These certifications can typically be verified through the respective regulatory bodies' official websites or by requesting documentation directly from Rubicon Research.

When conducting due diligence on Rubicon Research, consider the following steps:

• Regulatory Compliance: Verify FDA approvals, WHO prequalification, and EU GMP certifications.

• Financial Health: Review the company's financial statements for profitability and growth trends.

• Supply Chain Reliability: Assess the consistency and reliability of the company's supply chain and delivery timelines.

• Product Portfolio: Evaluate the breadth and depth of the company's product offerings, including any unique or proprietary formulations.

• Reputation: Research the company's reputation in the industry, including any past regulatory issues or quality concerns.

Red flags to watch for include unresolved regulatory violations, significant financial losses, or a history of product recalls. Recommended pre-order checks involve requesting recent regulatory certificates, financial reports, and customer references to ensure the company's credibility and reliability.